NeoGenomics
253 hedge funds and large institutions have $1.65B invested in NeoGenomics in 2019 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 104 increasing their positions, 75 reducing their positions, and 37 closing their positions.
103% more call options, than puts
Call options by funds: $4.94M | Put options by funds: $2.44M
39% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 75
3% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 37
0% more funds holding
Funds holding: 253 → 253 (0)
2% less ownership
Funds ownership: 86.05% → 84.05% (-2%)
14% less capital invested
Capital invested by funds: $1.91B → $1.65B (-$259M)
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$53M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$13.5M |
| 3 |
BlackRock
New York
|
+$9.16M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$7.39M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$6M |
Top Sellers
NEO Hedge Fund Activity: Q3 2019 in Review
253 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in NeoGenomics (NEO) for Q3 2019, worth a combined $1.65B — down 14% from $1.91B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new NEO positions and 37 closed out — a net gain of 1 holder — while 104 added to existing stakes and 75 trimmed.
The largest buyer was Vanguard Group, adding an estimated $53M. The largest seller was Marshall Wace, cutting an estimated $24.1M.
- 253 institutional investors held NeoGenomics (NEO) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $1.65B of NeoGenomics stock for Q3 2019, down 14% quarter-over-quarter.
- 38 funds opened new NeoGenomics positions in Q3 2019 and 37 closed out, a net change of +1 holder.
- The largest NeoGenomics buyer in Q3 2019 was Vanguard Group, an estimated $53M added.
- The largest NeoGenomics seller in Q3 2019 was Marshall Wace, an estimated $24.1M sold.
Based on aggregated 13F filings for Q3 2019.